Gilead, Novartis cancer therapies losing patients to experimental treatments

by reuter.com
https://ift.tt/pnED7n
Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc and Novartis AG , new data shows, helping explain why sales of the two products have not met rosy expectations.

Read more

Share on Facebook Share on Twitter Share on Google Plus

About New

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.